EKF Diagnostics (LON:EKF) Stock Passes Above 200 Day Moving Average - What's Next?

Key Points

• Technical breakout: EKF Diagnostics crossed above its 200‑day moving average (200‑day MA GBX 25.39) and traded at GBX 26 on heavy volume (~1.05 million shares), signaling potential upside momentum.
• Analyst sentiment: Stifel Nicolaus reiterated a Buy rating with a GBX 35 target, and MarketBeat shows a consensus Buy with a consensus target of GBX 35.
• Key fundamentals: Market cap ~£112.6m, P/E 55.55, debt/equity 2.01, last quarter EPS GBX 0.47 and analysts forecast ~GBX 2.30 EPS for the current fiscal year.

EKF Diagnostics Holdings plc (LON:EKF - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 25.39 and traded as high as GBX 26. EKF Diagnostics shares last traded at GBX 26, with a volume of 1,051,453 shares.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus reiterated a "buy" rating and set a GBX 35 target price on shares of EKF Diagnostics in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Buy rating, According to MarketBeat, EKF Diagnostics currently has a consensus rating of "Buy" and a consensus target price of GBX 35.

EKF Diagnostics Stock Performance

The firm has a market capitalization of £112.55 million, a price-to-earnings ratio of 55.55 and a beta of 0.49. The company has a fifty day moving average of GBX 24.87 and a two-hundred day moving average of GBX 25.39. The company has a debt-to-equity ratio of 2.01, a quick ratio of 1.77 and a current ratio of 4.16.

EKF Diagnostics (LON:EKF - Get Free Report) last released its quarterly earnings results on Tuesday, March 24th. The company reported GBX 0.47 earnings per share for the quarter. EKF Diagnostics had a return on equity of 3.01% and a net margin of 4.12%. As a group, equities research analysts predict that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current fiscal year.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.